Abstract
Importance Sarcopenia, or diminished skeletal muscle mass, is prognostic for survival in patients with head and neck cancer (HNC). However, identification of this high-risk feature remains challenging for patients without computed tomography (CT) images that capture the abdomen or lower thorax.
Objectives To (1) define sarcopenia thresholds at the C3 vertebral level using previously established thresholds derived from abdominal CT imaging and (2) determine if C3-defined sarcopenia is associated with survival in patients with HNC.
Design, setting, and participants This retrospective cohort study was conducted in consecutive patients with a squamous cell carcinoma of the head and neck with cross-sectional abdominal or neck imaging within 60 days prior to treatment and treated between January 2005 and December 2017. Data analysis was completed from December 2018 to April 2021.
Exposures Measurement of the cross-sectional muscle area at the third lumbar and cervical vertebral levels using CT imaging.
Main outcomes and measures Primary study outcome was overall survival.
Results In a cohort of 253 HNC patients with CT imaging that captures both L3 and C3 vertebral levels, skeletal muscle cross-sectional area at C3 was strongly correlated with the L3 level in both men (n = 188; r = 0.77; p < 0.001) and women (n = 65; r = 0.80; p < 0.001), and C3-defined sarcopenia thresholds of 14.0 cm2/m2 (men) and 11.1 cm2/m2 (women) were best predictive of previously established L3-defined sarcopenia thresholds. Applying these defined C3 sarcopenia thresholds in a cohort of 536 HNC patients with neck imaging alone revealed that C3-defined sarcopenia was independently associated with reduced overall survival in men (HR = 2.63; 95% CI, 1.79, 3.85) but not women (HR = 1.18, 95% CI, 0.76, 1.85) with HNC.
Conclusions and relevance This study identifies sarcopenia thresholds at the C3 level that best predict L3-defined sarcopenia in both men and women. In HNC, C3-defined sarcopenia is associated with poor survival outcomes in men, but not women, suggesting sarcopenia may differentially affect men and women with HNC.
Question Is cervical vertebrae muscle wasting a reliable predictor of sarcopenia-related mortality in patients with head and neck cancer (HNC)?
Findings (1) We established sex-specific sarcopenia thresholds (men, 14.0 cm2/m2; women, 11.1 cm2/m2) at the third cervical vertebrae (C3) level through statistical modelling that correlates with previously established lumbar thresholds. (2) Applying these defined C3 sarcopenia thresholds in a large cohort of HNC patients with neck imaging alone revealed that C3-defined sarcopenia was associated with reduced overall survival in men (HR = 2.63; 95% CI, 1.79, 3.85), but not women (HR = 1.18, 95% CI, 0.76, 1.85) with HNC.
Meaning The C3 sarcopenia thresholds established herein may be a useful prognostic and risk-stratification tool; the influence of sarcopenia on patient outcomes should be assessed in a sex-specific manner.
Competing Interest Statement
This work was supported National Cancer Institute grants CA245188 (Grossberg) and CA254033 (Olson). Dr. Fuller received/receives funding and salary support during the period of study execution unrelated to this work from: the National Institutes of Health (NIH) National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Program (R01CA214825); Joint NSF/NIH Initiative on Quantitative Approaches to Biomedical Big Data program (R01CA225190); NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787); NIH National Institute of Dental and Craniofacial Research (NIDCR) Academic Industrial Partnership Grant (R01DE028290); NIDCR Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions award (R01DE025248); NCI Parent Research Project Grant (R01CA258827); NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148); an NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672); a sub-award from the Small Business Innovation Research Grant Program (R43CA254559); a sub-award from the The Human BioMolecular Atlas Program (HuBMAP) Integration, Visualization & Engagement (HIVE) Initiative (OT2OD026675); the Patient-Centered Outcomes Research Institute (PCS-1609-36195); a National Science Foundation (NSF) Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) grant (NSF 1933369); and the NSF/NCI Smart connected Health Program (R01CA257814). Dr. Fuller receives infrastructure support from MD Anderson Cancer Center under the The Image Guided Cancer Therapy (IGCT) Research Program, and grant and infrastructure support via the Charles and Daneen Stiefel Center for Head and Neck Cancer Oropharyngeal Cancer Research Program. Dr. Fuller has received direct industry grant/in-kind support, honoraria, and travel funding from Elekta AB unrelated to this project.
Funding Statement
This work was supported National Cancer Institute grants CA245188 (Grossberg) and CA254033 (Olson). Dr. Fuller received/receives funding and salary support during the period of study execution unrelated to this work from: the National Institutes of Health (NIH) National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Program (R01CA214825); Joint NSF/NIH Initiative on Quantitative Approaches to Biomedical Big Data program (R01CA225190); NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787); NIH National Institute of Dental and Craniofacial Research (NIDCR) Academic Industrial Partnership Grant (R01DE028290); NIDCR Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions award (R01DE025248); NCI Parent Research Project Grant (R01CA258827); NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148); an NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672); a sub-award from the Small Business Innovation Research Grant Program (R43CA254559); a sub-award from the The Human BioMolecular Atlas Program (HuBMAP) Integration, Visualization & Engagement (HIVE) Initiative (OT2OD026675); the Patient-Centered Outcomes Research Institute (PCS-1609-36195); a National Science Foundation (NSF) Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) grant (NSF 1933369); and the NSF/NCI Smart connected Health Program (R01CA257814). Dr. Fuller receives infrastructure support from MD Anderson Cancer Center under the The Image Guided Cancer Therapy (IGCT) Research Program, and grant and infrastructure support via the Charles and Daneen Stiefel Center for Head and Neck Cancer Oropharyngeal Cancer Research Program. Dr. Fuller has received direct industry grant/in-kind support, honoraria, and travel funding from Elekta AB unrelated to this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board at Oregon Health and Science University. Requirement for informed consent was waived due to the retrospective nature of this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon reasonable request.
